Glucagon Like Peptide 1 (GLP-1) Analogs are synthetic peptide drugs that mimic the effects of naturally-occurring GLP-1 hormones which are responsible for stimulating insulin secretion, suppressing glucagon secretion and slowing gastric emptying. GLP-1 Analogs are administered via injections or inhalers and are used to treat Type 2 Diabetes by regulating blood glucose levels more efficiently than other anti-diabetic drugs. The development of long-acting GLP-1 Analogs such as once-weekly formulations have led to better patient compliance and adherence to treatment regimens.
The Global Glucagon Like Peptide 1 Analogs Market is estimated to be valued at US$ 18 Mn in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024 to 2030. Key Takeaways Key players operating in the Glucagon Like Peptide 1 Analogs market are Alcoa Corporation, Novelis Inc., UACJ Corporation, Norsk Hydro ASA, AMG Advanced Metallurgical Group, Constellium, Aluminum Corporation of China Limited, Rio Tinto Group, Aleris Corporation, Autoneum Holding AG, Dana Limited, ElringKlinger AG, Progress-Werk Oberkirch AG, JINDAL ALUMINIUM LTD., Kaiser Aluminum. Key players such as Novo Nordisk, Eli Lilly, Sanofi are witnessing rise in demand for their GLP-1 drug formulations owing to increasing global prevalence of diabetes and obesity. The growing global diabetic population, coupled with rising awareness about superior efficacy and safety of GLP-1 Analogs over other anti-diabetic drugs is expected to drive market growth. Furthermore, new product approvals and launches of once-weekly and long-acting GLP-1 Analog drugs will further aid in market expansion. The Glucagon Like Peptide 1 Analogs market is expanding globally with companies focusing on geographic expansion into high growth emerging markets of Asia Pacific, Latin America, Middle East and Africa. Partnerships with local distributors are helping key players penetrate rural areas and expand accessible patient pool. Market key trends Once-weekly Glucagon Like Peptide 1 Analogs Market Trend Analogs have emerged as a popular market trend. Drugs like Dulaglutide (Trulicity) by Eli Lilly, Semaglutide (Ozempic, Rybelsus) by Novo Nordisk offer superior clinical benefits and dosing convenience over existing daily GLP-1 formulations driving strong uptake. Their long duration of action helps drive medication adherence among diabetic patients significantly.
Porter's Analysis Threat of new entrants: New companies will find it difficult to enter this market as it requires huge initial investments for R&D and stringent regulatory approvals. Bargaining power of buyers: The buyers have weak bargaining power as there are limited options available in the market. Bargaining power of suppliers: Suppliers have some bargaining power due to their specialized ingredients and technologies required. Threat of new substitutes: Threat from new substitutes is low as GLP-1 Analogs are considered superior for certain conditions. Competitive rivalry: Intense competition exists among existing players due to their innovative pipeline and patent protection. The market for Glucagon Like Peptide 1 Analogs is concentrated majorly in North America due to higher healthcare spending and growing diabetes prevalence. The Asia Pacific region is witnessing the fastest growth due to rising awareness, increasing geriatric population and healthcare investments. Geographical Regions
North America accounts for the largest share of the Glucagon Like Peptide 1 Analogs market primarily due to advanced healthcare infrastructure and rising incidence of diabetes. According to International Diabetes Federation, more than 37.3 million Americans had diabetes in 2019. Asia Pacific region is poised to grow at the highest CAGR during the forecast period. This is attributed to rapidly improving healthcare sector, large patient pool, increasing lifestyle diseases and rising disposable incomes in emerging economies like China and India.
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
